Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.
Biomarker discovery
CD, Crohn's disease
CRP, C reactive protein
FDA, Food and Drug Administration
IBD
IBD, inflammatory bowel diseases
MOA, mechanism of action
Omics
Personalized medicine
Precision
RCTs, randomized clinical trials
SES, simple endoscopic score
TDM, therapeutic drug monitoring
TNF, tumour necrosis factor
Therapeutic ceiling
UC, ulcerative colitis
UST, ustekinumab
Journal
Current research in pharmacology and drug discovery
ISSN: 2590-2571
Titre abrégé: Curr Res Pharmacol Drug Discov
Pays: Netherlands
ID NLM: 9918300982506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
10
2021
revised:
23
12
2021
accepted:
21
01
2022
entrez:
11
2
2022
pubmed:
12
2
2022
medline:
12
2
2022
Statut:
epublish
Résumé
The past decades witnessed a significant stride in deciphering the pathophysiology of inflammatory bowel disease, which further advanced drug development adding several new biologicals and small molecules to the arsenal of available therapies. Surprisingly, this wealth in therapeutic options did not yield the aspired high durable response rates. In addition, the increase in therapeutic availabilities ignited an increase in research toward biomarkers that could help assign therapies to patients with the highest probability of response. Luckily, major steps have been undertaken in this domain which resulted in the discovery of some interesting biomarkers that are still under validation. However, the pace in which this domain is progressing, the discordance between short-term endpoints in biomarker discovery studies and the ambition of the disease community in modifying disease course, and the uncertainties about the validity of discovered biomarkers highlight the need for a critical appraisal of research conduct in this domain. In this review, we shed light on areas of improvement in biomarker discovery studies that will help optimize the use of available therapies and break the current therapeutic ceiling.
Identifiants
pubmed: 35146421
doi: 10.1016/j.crphar.2022.100089
pii: S2590-2571(22)00009-8
pmc: PMC8818904
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100089Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
B Verstockt reports financial support for research from Pfizer; lecture fees from Abbvie, Biogen, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda and Truvion; consultancy fees from Applied Strategic, Atheneum, Bristol Myers Squibb, Guidepoint, Ipsos, Janssen, Progenity, Sandoz, Sossei Heptares and Takeda. S Vermeire reports financial support for research: MSD, AbbVie, Galapagos, Takeda, Pfizer, J&J; Lecture fees from MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche; consultancy fees from MSD, AbbVie, Takeda, Ferring, Centocor, Hospira, Pfizer, J&J, Genentech/Roche, Celgene, Mundipharma, Celltrion, SecondGenome, Prometheus, Shire, Prodigest, Gilead, Galapagos. D Alsoud declares no conflicts of interest.
Références
Sci Rep. 2021 Mar 25;11(1):6865
pubmed: 33767314
Gastroenterology. 2021 Jul;161(1):353-355
pubmed: 33991577
J Crohns Colitis. 2017 Aug 1;11(8):921-929
pubmed: 28333288
Clin Transl Gastroenterol. 2016 Jan 07;7:e135
pubmed: 26741065
EBioMedicine. 2019 Feb;40:733-742
pubmed: 30685385
J Crohns Colitis. 2021 Sep 25;15(9):1431-1442
pubmed: 33730756
N Engl J Med. 2020 Dec 31;383(27):2652-2664
pubmed: 33382932
BMJ. 2006 May 6;332(7549):1080
pubmed: 16675816
Gut. 2019 Aug;68(8):1386-1395
pubmed: 31030191
Aliment Pharmacol Ther. 2020 May;51(9):831-842
pubmed: 32202328
Gastroenterology. 2021 Aug;161(2):394-399
pubmed: 33961886
Gut. 2019 Aug;68(8):1531-1533
pubmed: 30007919
Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10
pubmed: 31112238
Inflamm Bowel Dis. 2021 May 17;27(6):760-770
pubmed: 33438720
Nat Immunol. 2011 Apr;12(4):273-7
pubmed: 21423219
Cell. 2018 Apr 19;173(3):535-539
pubmed: 29677503
Therap Adv Gastroenterol. 2016 Jul;9(4):513-26
pubmed: 27366220
Front Pharmacol. 2021 Apr 14;12:651415
pubmed: 33935763
United European Gastroenterol J. 2019 Jul;7(6):750-758
pubmed: 31316779
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Gut. 2020 Aug;69(8):1520-1532
pubmed: 32111636
J Crohns Colitis. 2021 Aug 06;:
pubmed: 34355244
Front Immunol. 2021 Mar 15;12:627535
pubmed: 33790898
Gastroenterology. 2021 Apr;160(5):1452-1460.e21
pubmed: 33421515
Inflamm Bowel Dis. 2015 Jan;21(1):182-97
pubmed: 25222660
Gut. 2019 Jan;68(1):25-39
pubmed: 29730603
Gastrointest Endosc. 2015 Aug;82(2):246-55
pubmed: 26005012
Gut. 2020 Oct 26;:
pubmed: 33106355
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):589-595
pubmed: 34019798
Aliment Pharmacol Ther. 2020 Apr;51(7):737-738
pubmed: 32162373
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):429-437
pubmed: 33887262
BMC Health Serv Res. 2021 Aug 18;21(1):836
pubmed: 34407821
Pharm Stat. 2009 Jan-Mar;8(1):50-61
pubmed: 18389492
J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8
pubmed: 18840817
Nat Rev Dis Primers. 2020 Sep 10;6(1):74
pubmed: 32913180
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Nat Rev Dis Primers. 2020 Apr 2;6(1):22
pubmed: 32242028
Gut. 2019 Apr;68(4):604-614
pubmed: 29618496
Gastroenterology. 2021 Apr;160(5):1570-1583
pubmed: 33359090
J Clin Med. 2020 Aug 14;9(8):
pubmed: 32823997
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66
pubmed: 33033392
Am J Gastroenterol. 2020 Aug;115(8):1236-1245
pubmed: 32759621
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
J Crohns Colitis. 2020 Mar 13;14(3):332-341
pubmed: 31504343
Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii
pubmed: 26611548